W
WAVEMAN · COMPANY
NSRX · Nasus Pharma Ltd
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

NSRX

Nasus Pharma Ltd
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002029039
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$61.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
5
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-0.5%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$61.8K over 180 days
+$20.3K over 90 days
more than 74% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
5 funds added or opened last quarter
below 96% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
-0.5% net margin
more than 65% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
1.8% of shares outstanding short · 15.2 days to cover · settled 2026-07-31
below 66% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -53.1%
-53.1%12M
-75%-45%-16%+14%2025-092025-102025-122026-032026-052026-072026-09 2026-03-31 · Teleman Dan Benjamin bought $30.6K2026-06-17 · Teleman Dan Benjamin bought $20.3K2026-04-22 · Teleman Dan Benjamin bought $10.9K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $61.8K bought by insiders over 180 days, 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Nasus Pharma Ltd insiders bought a net $61.8K of stock across 3 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Teleman Dan Benjamin
Chief Executive Officer
BUY
2026-06-17
6,550.0
$20.3K
Teleman Dan Benjamin
Chief Executive Officer
BUY
2026-04-22
2,900.0
$10.9K
Teleman Dan Benjamin
Chief Executive Officer
BUY
2026-03-31
15,000.0
$30.6K
3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Balyasny Asset Management L.P.
898,473.0 sh
$3.1M
Cable Car Capital, LP
616,081.0 sh
$2.2M
Velan Capital Investment Management LP
359,390.0 sh
$1.3M
Hudson Bay Capital Management LP
134,771.0 sh
$471.7K
Bleichroeder LP
89,848.0 sh
$314.5K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
3
Multi-phase
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-12
REVENUE$1.2B
OPERATING INCOME$-4.9M$-1.1M$-1.1M
NET INCOME$-5.9M$-1.5M$-1.1M
EPS (DILUTED)-0.72-0.22-0.20
OPERATING CASH FLOW$-4.9M$-665.0K$-1.0M
CASH$1.2M$284.0K$193.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →